Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://tiffanyjjhf855853.corpfinwiki.com/10057263/retatrutide_australia_a_new_breakthrough_for_obesity_treatment